Cargando…
Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia
Morbidity and mortality from COVID-19 is due to severe inflammation and end-organ damage caused by a hyperinflammatory response. Multiple immunomodulatory agents to attenuate this response have been studied. Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospital...
Autores principales: | McManus, Dayna, Davis, Matthew W., Ortiz, Alex, Britto-Leon, Clemente, Dela Cruz, Charles S., Topal, Jeffrey E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678826/ https://www.ncbi.nlm.nih.gov/pubmed/37085221 http://dx.doi.org/10.1016/j.ccm.2022.11.009 |
Ejemplares similares
-
2688. The Clinical Impact of Early De-escalation of Broad-Spectrum Antibiotics in Acute Myeloid Leukemia Patients with Febrile Neutropenia
por: Davis, Matthew, et al.
Publicado: (2019) -
308. Re-purposing Beta-lactam Antibiotics as Fluoroquinolone Sparing Stepdown Therapy for the Treatment of Enterobacteriales Bloodstream Infections
por: Davis, Matthew, et al.
Publicado: (2020) -
Response
por: Price, Christina C., et al.
Publicado: (2021) -
Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients
por: Davis, Matthew W., et al.
Publicado: (2020) -
Successful Use of Ertapenem for the Treatment of Enterobacter cloacae Complex Infection of the Central Nervous System (CNS)
por: Shah, Sunish, et al.
Publicado: (2019)